PharmaCyte Biotech Inc (PMCB) — Net Asset Quality Index
PharmaCyte Biotech Inc (PMCB) has a Net Asset Quality Index of 70.5% as of January 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $55.87 Million minus total liabilities of $16.47 Million yields net assets of $39.40 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check PMCB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
PharmaCyte Biotech Inc Net Asset Quality Index Over Time (2004–2025)
This chart shows how PharmaCyte Biotech Inc's Net Asset Quality Index has evolved across 22 annual periods from 2004 to 2025. As of January 2026, the index stands at 70.5%, representing net assets of $39.40 Million against total assets of $55.87 Million USD. See PMCB net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for PharmaCyte Biotech Inc (2004–2025)
The table below presents the year-by-year Net Asset Quality Index for PharmaCyte Biotech Inc from 2004 to 2025, covering 22 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of PharmaCyte Biotech Inc.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 94.1% | $51.89 Million | $55.17 Million | $3.28 Million | ▲ +28.1 pp |
| 2024 | 66.0% | $39.51 Million | $59.90 Million | $20.39 Million | ▼ -33.2 pp |
| 2023 | 99.2% | $72.69 Million | $73.28 Million | $586.58K | ▼ 0.0 pp |
| 2022 | 99.2% | $89.92 Million | $90.62 Million | $704.37K | ▲ +9.0 pp |
| 2021 | 90.2% | $6.68 Million | $7.40 Million | $724.78K | ▲ +7.7 pp |
| 2020 | 82.5% | $5.09 Million | $6.17 Million | $1.08 Million | ▼ -4.6 pp |
| 2019 | 87.2% | $5.04 Million | $5.78 Million | $742.85K | ▼ -2.8 pp |
| 2018 | 90.0% | $5.77 Million | $6.41 Million | $644.17K | ▼ -3.4 pp |
| 2017 | 93.3% | $8.09 Million | $8.67 Million | $580.25K | ▲ +2.2 pp |
| 2016 | 91.1% | $6.52 Million | $7.16 Million | $637.64K | ▲ +16.4 pp |
| 2015 | 74.7% | $5.94 Million | $7.95 Million | $2.01 Million | ▼ -21.3 pp |
| 2014 | 96.0% | $8.94 Million | $9.32 Million | $373.67K | ▲ +128.0 pp |
| 2013 | -32.0% | $-921.46K | $2.88 Million | $3.80 Million | ▲ +77.2 pp |
| 2012 | -109.2% | $-2.28 Million | $2.09 Million | $4.37 Million | ▲ +110.9 pp |
| 2011 | -220.1% | $-2.73 Million | $1.24 Million | $3.97 Million | ▼ -57.8 pp |
| 2010 | -162.3% | $-1.95 Million | $1.20 Million | $3.15 Million | ▼ -220.6 pp |
| 2009 | 58.3% | $3.99 Million | $6.84 Million | $2.85 Million | ▼ -39.3 pp |
| 2008 | 97.6% | $7.44 Million | $7.62 Million | $180.56K | ▲ +0.3 pp |
| 2007 | 97.3% | $4.29 Million | $4.41 Million | $118.81K | ▲ +11.4 pp |
| 2006 | 85.9% | $4.41 Million | $5.14 Million | $723.89K | ▲ +470.9 pp |
| 2005 | -385.0% | $-1.30 Million | $336.36K | $1.63 Million | ▼ -297.7 pp |
| 2004 | -87.3% | $-153.43K | $175.71K | $329.13K | — |